Zhao et al. (2021) developed a novel 99mTc-labeled anti-HER2 single-domain antibody (99mTc-NM-02) and investigated its safety, radiation dosimetry, biodistribution, and tumor-targeting potential in 10 patients with HER2-positive breast cancer. Here, ERBB2 is linked to neoplasm.